According to WHO, cardiovascular diseases (CVDs) cause around 17.9M death yearly at global level . Growing evidence demonstrates how the combination of different metabolic comorbidities can affect the development of CVDs. Hence, the risk of cardiovascular disease (CVD) is not solely attributed to a single factor, but rather to a multifaceted condition. For instance, metabolic syndrome (MetS) is characterized by a combination of interrelated factors that directly elevate the risk of coronary heart disease. It is mainly characterized by at least three concomitant hallmarks among dyslipidemia, high blood pressure, dysregulated glucose homeostasis, insulin resistance, and abdominal obesity . Similarly, non-alcoholic fatty liver disease (NAFLD) is commonly recognized as the hepatic expression of metabolic syndrome .